IGHE and neoplasm: The ongoing Phase 1 clinical study (NCT02546921, www.clinicaltrials.gov) of MOv18, a first-in-class therapeutic IgE antibody for ovarian cancer therapy, represents a substantial advance for the field, and it underlines the importance of further exploration of the safety profile and clinical applicability of IgE therapeutics against different tumor targets.